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Purpose: To develop a high-resolution three-dimensional (3D) magnetic resonance imaging (MRI)-
based treatment planning approach for uveal melanomas (UM) in proton therapy.
Materials/methods: For eight patients with UM, a segmentation of the gross tumor volume (GTV)
and organs-at-risk (OARs) was performed on T1- and T2-weighted 7 Tesla MRI image data to recon-
struct the patient MR-eye. An extended contour was defined with a 2.5-mm isotropic margin derived
from the GTV. A broad beam algorithm, which we have called pDose, was implemented to calculate
relative proton absorbed doses to the ipsilateral OARs. Clinically favorable gazing angles of the trea-
ted eye were assessed by calculating a global weighted-sum objective function, which set penalties
for OARs and extreme gazing angles. An optimizer, which we have named OPT’im-Eye-Tool, was
developed to tune the parameters of the functions for sparing critical-OARs.
Results: In total, 441 gazing angles were simulated for every patient. Target coverage including mar-
gins was achieved in all the cases (V95% > 95%). Over the whole gazing angles solutions space, maxi-
mum dose (Dmax) to the optic nerve and the macula, and mean doses (Dmean) to the lens, the ciliary
body and the sclera were calculated. A forward optimization was applied by OPT’im-Eye-Tool in three
different prioritizations: iso-weighted, optic nerve prioritized, and macula prioritized. In each, the func-
tion values were depicted in a selection tool to select the optimal gazing angle(s). For example, patient
4 had a T2 equatorial tumor. The optimization applied for the straight gazing angle resulted in objec-
tive function values of 0.46 (iso-weighted situation), 0.90 (optic nerve prioritization) and 0.08 (macula
prioritization) demonstrating the impact of that angle in different clinical approaches.
Conclusions: The feasibility and suitability of a 3D MRI-based treatment planning approach have
been successfully tested on a cohort of eight patients diagnosed with UM. Moreover, a gaze-angle
trade-off dose optimization with respect to OARs sparing has been developed. Further validation of the
whole treatment process is the next step in the goal to achieve both a non-invasive and a personalized
proton therapy treatment. © 2020 The Authors. Medical Physics published by Wiley Periodicals LLC
on behalf of American Association of Physicists in Medicine. [https://doi.org/10.1002/mp.14665]
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1. INTRODUCTION
Uveal melanoma (UM) originates mostly from the choroid
and less frequently in the ciliary body and iris areas. Proton
therapy for uveal melanoma is one of the main radiotherapy
options for treating these malignant intraocular tumors,1–12
enabling both improved dose distribution homogeneity and
sharp dose gradients. Proton therapy is suitable for large and
peri-papillary/-macular uveal melanomas, and it is mostly
delivered by dedicated passive scattering horizontal beam-
lines.3,13
The clinical workflow, including surgery for clips
placement, in-room simulations and positioning, planning
and treatment completions, has been described in detail by
a wide spectrum of publications over the last four
decades.8,14–18 In short, patients undergo surgery prior to
proton therapy, with clips stitched onto the sclera to out-
line the tumor boundary. The purpose of these invasive
clips is twofold: first, to delineate the tumor volume
within a geometrical-based eye model; second, to position
and verify the correct gazing angle during treatment. For
planning, a series of X-ray images of the eye are acquired
at different gazing angles and imported into the treatment
planning system (TPS) for the selection of the optimal eye
model and target delineation. Subsequently, the optimal
gazing angle of the eye for the treatment is defined by a
manual rotation of the eye model around its center, and
dose parameters are evaluated in a manual manner by a
trade-off between target coverage and sparing of specific
organs-at-risks (OARs). The optimal gazing angle selection
can also be automated as demonstrated by the Paul Scher-
rer Institute team (PSI, Villigen, Switzerland).19
Manual and automatic treatment planning procedures are
both currently limited by the lack of accurate 3D information
for target and OARs definition. The Deutsches Krebs-
forschungszentrum (DKFZ, Heidelberg, Germany) in partner-
ship with the Helmholtz-Zentrum in Berlin have developed
OCTOPUS20 (Ocular Tumour Planning UtilitieS) for inte-
grating a more complex eye model definition. In this TPS, the
eye model is interactively adapted to computed tomography
(CT) or magnetic resonance imaging (MRI) datasets21 and
afterwards it is registered to the image data. Since diagnosis
of uveal melanomas increasingly incorporates MRI informa-
tion,22–24 there is a need to develop MRI-based treatment
planning. The MR-compatibility of tantalum clips, which are
currently being used as landmarks, has been proved.25 In
addition, 3 and 7 Tesla high-resolution MRI sequences have
been developed to enable improved UM and OARs delin-
eation compared to conventional MRI procedures which do
not clearly discriminate ocular structures.26 The Paul Scherrer
Institute is currently also investigating how MRI sequences
can be used for improvement in the eye model definition.27
This emerging imaging modality strengthens the justification
to shift toward MRI for ocular proton therapy planning with
the ultimate goal of providing a non-invasive, that is, clipless,
ocular proton therapy treatment.
The aim of this project was to assess the feasibility of
implementing a full 3D MRI-based treatment planning
approach with a gaze-angle proton dose optimization from 7
Tesla high-resolution MRI data. To our knowledge, currently
no system incorporates these two cutting-edge approaches,
MRI-based delineation and automatic treatment planning,
into one dedicated platform.
2. MATERIALS AND METHODS
2.A. Outline
The 3D MRI-based ocular proton therapy treatment plan-
ning approach, with a gaze-angle dose optimization can be
broken down into the following steps. The first step is the
acquisition of high-resolution 3D MRI images. Afterwards, a
semi-automatic segmentation of all relevant structures is per-
formed for 3D MRI-based patient-specific eye reconstruction,
which is used for the next step, calculation and evaluation of
the dose distribution within the eye. The last step is a forward
optimization to improve and simplify the selection of the
optimal gazing angle(s) for the treatment.
2.B. Patients and data collection
Eight patients referred by the Department of Ophthal-
mology at Leiden University Medical Center were diag-
nosed in 2018 with a primary uveal melanoma and no
evidence of extrascleral extension. All patients were retro-
spectively included in this study (Fig. 1). Five patients had
right and three patients left eye melanomas (Table I). The
uveal melanomas involved the equator in 37.5% of the
patients and were located posteriorly, meaning at a maxi-
mum 3-mm distance2 of the optic nerve in 67.5% of the
cohort. The median tumor thickness and basal diameter
were 6 and 12 mm, respectively (ranges: 3 to 12 mm and
8 to 18 mm). Three patients had T1 melanoma, 2 at T2
stage and 3 at T3 stage according to the international
Tumor Node Metastasis (TNM) classification.28 The clos-
est mean border-to-border 3D surface-mesh distance from
the tumor to the optic nerve was 2.6 mm (median, min,
max) = (1.5, 0, 12 mm) and to the macula was 3.9 mm
(median, min, max) = (3.7, 0, 14 mm). MR-tumor promi-
nences and thicknesses were manually measured by the
same ocular radio-oncologist and TNM classification fol-
lowed the consensus staging forms from the American
Joint Committee on Cancer, Eighth Edition.28
With the aim of providing a comparison between the cur-
rent geometrical approach and the proposed 3D MRI-based
treatment planning approach, additional clinical information
was collected for patient 3, who presented a macular area
tumor. For this patient, tumor dimensions were determined
using high frequency ultrasound images (10MHz, Quantel
Medical Aviso, Cournon d’Auvergne, France): promi-
nence = 4 mm; diameter (min 9 max) = (11.8 9 12.0 mm).
Visual inspection of fundus photography was used to adjust
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the contour of the tumor base and determine an accurate mac-
ula positioning.
2.C. Ocular imaging data
2.C.1. 7 Tesla high-resolution MRI patient imaging
protocol
For the development and testing of the high-resolution
MRI ocular proton therapy treatment planning approach,
MRI data from a single institution were collected. The study
was approved by the Institutional ethics board and followed
the recommendation of the Declaration of Helsinki. Written
informed consent was obtained from all the patients of the
study prior to their MRI scan. The orbits were imaged with a
Philips 7 Tesla Achieva whole-body MRI (Philips Healthcare,
Best, The Netherlands). A dedicated mask supporting a cus-
tom-made three-channel micro-eye-coil array has been
designed in-house and wore by every patient. The patient
head was immobilized in a volume transmit head coil (Nova
Medical Inc., Wilmington, MA, USA). None of retro- or
peri-bulbar anesthesia was provided during the MRI acquisi-
tion; the patients were instructed before the scan to adhere to
the cued blinking acquisition scheme. They were asked to
alternatively focus on a Maltesian cross, while quickly blink-
ing their eyes at an indicated time of every 3 s. Sequences to
offset eye-motion artefacts were performed, as previously
described.22–24 The complete MR-protocol included two
scans with an isotropic resolution, specifically designed for
radiotherapy planning. Parameters were as follows:
1. Three-dimensional gradient echo T1-weighted scan
(TI/TR/TE/FA: 1280 ms/5.4 ms/2.4 ms/7 deg); FOV:
40 mm 9 45 mm 9 38 mm; isotropic voxel size res-
olutions: (0.6 mm)3 for acquisition and (0.3 mm)3 for
reconstruction.
2. Three-dimensional turbo spin echo T2-weighted scan
(TR/TE: 2500 ms/203 ms with SPIR); FOV:
40 mm 9 47 mm 9 38 mm; isotropic voxel size res-
olutions: (0.6 mm)3 for acquisition and (0.3 mm)3 for
reconstruction.
These two dedicated clinical MRI protocols enabled to
perform imaging in a scan time of 3 min and 3 s for T1-
weighted images and 2 min and 53 s for T2-weighted
images. Additionally, contrast-enhanced T1-weighted images
FIG. 1. Patient cohort. Three-dimensional (3D) T1-weighted magnetic resonance (MR)-slices and reconstructed eyes with segmented MR contours: lens (blue);
ciliary body (purple); optic nerve (green); sclera ring (beige); tumor (red). The white arrows indicate the uveal melanoma. Note that the macula (orange) is ellip-
soidal-like shaped and only visible through the 3D-reconstructed MR-eyes, temporal side to the optic nerve head.
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were acquired after intravenous injection of 0.1 mmol/kg
gadoterate meglumine (gd-DOTA, DOTAREM, Guerbet,
Roissy CdG Cedex, France).
2.C.2. Semi-automatic MRI-segmentation
In-house algorithms have been developed to semi-auto-
matically segment eye anatomies and uveal melanomas on no
contrast-enhanced T1- and T2-weighted images.29 The center
of the eye was estimated on T2-weighted images using the
fast-radial symmetry transform.30 This center was used to
build a 3D-triangulated-surface mesh to detect the inner and
outer borders of the sclera and the tumor boundary itself. The
inner scleral mask (including the cornea) was created to reg-
ister T1- and T2-weighted images using Elastix,31,32 with nor-
malized mutual information as a similarity metric. Vitreous
body and lens segmentations were carried out on axial T1-
weighted images using fuzzy C-means clustering. These
masks were subsequently subtracted from the sclera mask to
segment the tumor. Once the tumor segmentation step was
completed, the contrast-enhanced T1-weighted images were
used to assess and manually validate that no retinal detach-
ment was actually included within the tumor volume. Know-
ing that the ciliary body expands the lens structure, its
segmentation was performed as follows: the two perpendicu-
lar axis maximizing the geometry of the lens in the axial
plane where found by applying principal component analysis.
The shortest axis of the lens (anterior–posterior direction)
was used to locate two perpendicular planes located in the
upper and lower extremes of the lens structure. The volume
constrained by these planes along the consecutives MRI
slices established the searching space where the ciliary body
had to be contained. By using an iterative closest point algo-
rithm, an inscribed polygon superquadric (i.e., donut-like
shape), and centered at the center-of-mass of the lens, was fit-
ted to the boundaries of the ciliary body. In the current imple-
mentation, the ring-shaped ciliary body segmentation
consists mainly of the ciliary muscle. The parts of the ciliary
body anteriorly attached to the sclera as well as the suspen-
sory ligaments connected to the lens are hardly differentiable
on our MRI images with the dedicated protocols developed
for radiotherapy planning purposes. The optic nerve sheath
was segmented on T1-weighted image using tubular tracking
algorithm, after defining a seed point on the optic nerve, fol-
lowed by mesh fitting. The algorithms were developed using
the rapid-prototyping platform MeVisLab (Fraunhofer
MeVis, Bremen, Germany). The macula was determined as
an ellipsoid and its position was based on a geometrical defi-
nition33 as it is not visible on MRI. It followed the geometri-
cal approximation currently implemented in the TPS Eclipse
Ocular Proton Planning (EOPP, Varian Medical Systems,
Inc., Palo Alto)33, that is, a longitudinal radius of 1 mm, a
transversal radius of 0.44 mm and a thickness of 1.5 mm.
The skin plane was defined as a plane parallel to the surface
entrance and passing through the center-of-mass of the 3D-
MRI triangulated-surface mesh of the lens. However, both
macula position and skin plane distance from the anterior
cornea can be adjusted to the physical value and position of
the individual patient. As retractors will be used during the
treatment to keep eyelids away from the beam path, the eye-
lids were not delineated as OARs.
2.C.3. Ocular motility
To complete the solutions space with all the gazing angles,
a 3D rotational movement of the eye was simulated. The eye
orientation was described by a sequence of rotations using
the modified IEC 61217 fixed horizontal beamline notation
convention. The primary position of the eye was defined as
the rest position, corresponding to a straight gazing angle.
All other positions were defined according to the gazing
direction. The center of rotation was defined as the center-of-
mass of the 3D-MRI triangulated-surface mesh of the sclera
ring29 (see supplementary materials) and its position was
considered the same for all the gazing angles over the solu-
tions space.
2.D. pDose and beam shaping patient-specific
components
An in-house developed dose engine pDose (Proton Eye
Dose) has been used for this study. pDose is based on a semi-
analytical broad beam algorithm similarly to the one pro-
posed by Koch and Newhauser.34 The supplementary materi-
als section provides details about the algorithm and its
preliminary validation.
Essential beam modifying devices that are always present
during the irradiation, that is, including scatter foils, variable
range shifters, range modulator wheels and beam collimator,
have been implemented. The first three beam modifying
devices are beamline-dependent and their physical properties
are defined during the commissioning and summarized in
look up tables for computational efficiency. Variable range
shifters and range modulator wheels are used to improve the
dose distribution conformity in depth, as a single native
Bragg peak is insufficient to shape the dose to cover the tar-
get volume. A spread-out Bragg Peak (SOBP) was created by
adding contributions of individual weighted Bragg peaks
generated by the range modulator wheels. The plateau of the
SOBP was normalized at 100% of the maximum dose. The
definitions of the depth of the penetration (i.e., the range R90)
and the width of the SOBP were characterized by the Interna-
tional Commission on Radiation Units and Measurements,
report 78.35 The width of the SOBP was defined by the
length of the tumor with addition of 2.5-mm margin distally
and proximally in the gazing direction and along the beam
central axis. Currently, the dose calculation is relative but it
might be translated to absolute dose for a fully characterized
beamline.
The beam collimator is patient-specific and shapes the
dose laterally based on the Beam’s-Eye-View of the tumor
contour with an added circumferential lateral margin back
projected at the snout location. The lateral margin was 2.5-
mm expansion of the Gross Tumor Volume. For treatment
Medical Physics, 0 (0), xxxx
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planning purposes, the collimator was assumed to be an ideal
absorber, acting as an infinitesimal thin and completely
absorbent material, while the proton beam was also assumed
to be uniform. All the plans were created with the 50% iso-
dose encompassing the target with the margin laterally.
All the three margins (lateral, distal and proximal) were
defined based on a worldwide clinical consensus.8,9,15,17,36–39
2.F. OPT’im-Eye-Tool: a forward gazing plan quality
optimization
An interactive manual decision-making tool has been
developed for the gazing angle optimization. The tool was
based on global weighted-sum objective functions computed
for each gazing angle. Those functions were calculated for
all ocular structures to be spared during the treatment. Each
structure can be prioritized by modifying weights to a speci-
fic dose-volume parameter, for example, the mean dose
(Dmean) to the lens, the ciliary body and the sclera, and max-
imum dose (Dmax) to the optic nerve and the macula. Addi-
tionally, a linearly defined parameter was used to penalize
extreme gazing angles located at the periphery of the
patient’s field of view. For example, zero penalty was given
for the primary position (straight gaze) where the extraocular
muscles exhibit minimum force so it is the easiest gazing
angle to hold for a patient, whereas extreme gazing angles at
the periphery of the field of view received the highest penal-
ties. The tumor coverage was not included in the optimizer,
as the definition of the broad beam ensures full coverage of
the target volume.
The forward optimization process was performed by calcu-
lating the dose distribution for all the gazing angles of the
solutions space. Objective function values were retrieved.
Planners can change OAR weights on a trial-and-error basis
to evaluate how prioritization affects the optimal gazing angle
selection. Weights were strictly positively defined and
summed up consistently to unity. A gazing angle-dependent
map has been developed to visualize the global weighted-
sum objective function values, where each calculated gazing
angle function value was displayed by the two angles [Ψ; ɸ].
Ψ represents any elevation/depression of the eye, whereas ɸ
represents any ab-/adduction (Fig. 3). For this study, parame-
ters Ψ and ɸ defined the patient field of view and ranged
between 30 to +30 degrees with an increment of 3 degrees
for both elevation/depression and add-/abduction. This map-
ping mimics the in-room gazing template which will be used
to guide the patient gazing direction using an LED light. The
optimal gazing angles ranges can be selected by the lowest
global weighted-sum objective function values.
3. RESULTS
3.A. Dose distributions over the gazing angles
solutions space
An example of 3D T1- and T2-weighted MR-slices with
delineation and the relative proton dose distribution
calculated with pDose is shown for patient 6 (Fig. 2). Table I
summarizes the dosimetric results for the whole cohort. The
resulting ipsilateral doses to OARs, Dmax to both optic nerve
and macula and Dmean to the lens, ciliary body and the sclera
ring are also detailed in Table I. For all 441 simulated gazing
angles per patient, the target coverage including margins
(V95% > 95%) was always achieved. The table presents the
average of all dosimetric results over the gazing angles solu-
tions space for every patient, presented by Dmin, Dmedian and
Dmax relative proton absorbed dose in the considered ocular
volume of interest (%).
Examples of interactive planning obtained from the
OPT’im-Eye-Tool optimizer are shown in Fig. 3, which dis-
play the gazing angle-dependent grid maps. In an iso-
weighted situation, the weights for the five OARs and for the
gazing angle were equally set to 0.17 whereas in either the
optic nerve or macula prioritized situations, weights were
assigned to 0.8 for the optic nerve (or macula) and 0.04 to
other OARs. Each colored area represented a specific gazing
angle, conjugated by a coupling of [Ψi; ɸj]. The values of the
function obtained for the straight gazing angle for the patients
of the cohort and for all three prioritizations are also given in
Table I. For posterior T1 tumors near the optic nerve and
macula (patients 1 to 3), only well-defined extreme gazing
angles located at the periphery of the field of view would
result in acceptable global weighted-sum objective function
values; otherwise, any change on gazing direction would
result in high global weighted-sum objective function values
in both optic nerve and macula prioritizations. Equatorial
tumors (i.e. patients 4, 6, 7), due to their localization and dis-
tance further away from critical OARs, enable more choices
to select optimal gazing angles, especially in the attempt of
sparing the macula. Regarding patient 4, the values of the
objective function for the straight gazing angle were 0.46
(iso-weighted prioritization), 0.90 (optic nerve prioritization)
and 0.08 (macula prioritization). To this end, looking straight
or downward would be more suitable for macula sparing in
that patient. For patient 6, who had a T3 equatorial tumor, the
distance between the tumor and both optic nerve and macula
edges were 7 and 9 mm, respectively, which enables a full
sparing of these two ocular organs. Although, an attempt to
spare the optic nerve would result in selecting one gazing
angle located at the periphery of the field of view, looking
straight would be suitable for a full sparing of the macula.
For patient 5, who had a posterior T2 tumor, gazing at the
straight direction would be optimal for macula sparing (ob-
jective function value of 0.40, Table I); on the other hand, if
the highest priority would be given to spare the optic nerve,
the straight direction should be avoided (objective function
value of 0.94, Table I). Patient 8 had a T3 nasal tumor almost
fully covering the optic nerve and its tumor edge was located
more than 3 mm away from the macula. In this situation, top
quadrant of the gazing mapping corresponding to eyeball ele-
vation would be the optimal solution in an iso-weighted situa-
tion; optic nerve and macula situations resulted in high
function values for the straight gazing angle (0.96 both),
which should be avoided.
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3.B. Comparison with geometrically based
treatment planning concept
To demonstrate the geometrical and dosimetrical accuracy
of the developed treatment planning system, a treatment plan
for patient 3 with a small T1 posterior tumor was created in
EOPP as well as in pDose (Fig. 4). Fundus photography and
ultrasound images were used to generate a geometrical model
of the eye and target structure in EOPP as well as to check the
outcome of the MR-tumor base delineation and macula posi-
tioning. A straight gazing angle was chosen in both planning
systems to provide a clear demonstration of the similarities
and differences between the two approaches. Both systems
resulted in the same range penetration and range modulation
within 1 mm agreement. The shapes and volumes of the tar-
get and OARs are different.
4. DISCUSSION
In this study, the feasibility of implementing a high-resolu-
tion 3D MRI-based treatment planning approach with a gaze-
angle proton dose optimization into one platform dedicated
to the treatment of ocular tumors has been presented. MR-
based reconstruction of the patient eye without any surgical
clip was performed with a semi-automatic segmentation of
the ocular structures and tumor. The segmentation was incor-
porated into an in-house developed treatment planning sys-
tem based on a semi-analytical broad beam algorithm. The
dose calculation with a forward gazing angle optimization
was then performed directly on the reconstructed MR-eye.
The first particularity of the modern treatment planning
system for ocular proton therapy proposed in the study, is the
use of 3D MRI to segment the eye and the relevant structures
of an individual patient eye anatomy. This approach can
reduce the discrepancies and uncertainties in volume and
shape definition that exist within the generic geometrical
models currently used in clinics, which are not patient-spe-
cific.40–42 Along the manuscript, it has been demonstrated
(Fig. 4) that our in-house developed treatment planning sys-
tem is geometrically and dosimetrically accurate. However,
all delineated structures differ in shape and size in compar-
ison to the clinically used geometrical approach, due to the
(a) (c)
(b)
FIG. 2. Demonstration of developed planning tools: three-dimensional (3D) T1- (a) and T2-weigthed (b) magnetic resonance (MR)-slice showing the uveal mela-
noma and delineated MR ocular anatomical structures (ON: Optic nerve; L: Lens; CB: Ciliary body; S: Sclera ring. (c) 3D relative proton dose distribution within
the 3D-MR-based reconstructed eye, calculated by pDose. The macula is geometrically defined.
FIG. 3. Resulting gazing-angle dependent heat maps depicting the global weighted-sum objective function values in iso-weighted, optic nerve prioritized and
macula prioritized optimizations. The colder colors (in blue) represent the lower objective function values, and therefore, preferable gazing angles for a treatment.
Field of view ranged between 30 to +30 degrees, both for add-/abduction and elevation/depression, with increments every 3 degrees. A total of 441 gazing
angles were simulated for every patient.
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intrinsic differences between both methods, which hampers a
proper comparison between our output vs the current clinical
practice. Therefore, intensive investigation involving larger
cohort of patients are required to carefully adapt the current
clinical concepts to MRI-based treatment planning, in order
to exploit its full potential and to maintain high local tumor
control. New definition of margins as well as organs-at-risk
constraints is likely to be needed. Rigorous quantification
and mitigation of treatment-related uncertainties should be
part of these studies.
Despite the availability of advanced sophisticated ocular
biomechanical models as well as recent methods such as Sta-
tistical Shape Models,27,43 simple geometrical modeling
based on ellipsoidal eye shape remains the current standard
deployed into the TPS such as EYEPLAN44–46 and Eclipse
Ocular Proton Planning (EOPP, Varian Medical Systems,
Inc., Palo Alto).33 The geometrical models are scaled close to
the individual anatomy using patient-specific parameters such
as naso-temporal, sagittal, anteroposterior and limbus diame-
ters of the eye as well as the edge of the tumor to papilla dis-
tance and interclips distances. These dimensions and
measurements are based on intraoperative caliper measure-
ments and information from fundus photography,46 ocular
biometry, ultrasound images and/or CT/MRI. Nevertheless,
those geometrical models may in some cases significantly
differ from the real patient anatomy. Slopsema et al.18
recently evaluated the differences in clip position between an
eye definition based on geometrical modeling as provided by
the EYEPLAN TPS and a modified eye model based on CT-
guided simulation. They demonstrated that the position of the
FIG. 4. Treatment plan comparison for patient 3 (T1 posterior tumor). (a) Fundus photography and (b, c) Ultrasound images. (d) Three-dimensional magnetic
resonance imaging (MRI)-based reconstructed eye and pDose treatment plan. The macula (orange) is geometrically shaped. Fundus photography was used in
conjunction with MR information for macula positioning and appreciation of the tumor base delineation. (e) Geometrical approach and EOPP TPS treatment
plan. Eye and tumor were modeled based on the ultrasound images and fundus photography.
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clips is more accurately modeled for specific cases in the lat-
ter when 3D CT information was incorporated.
Hitherto, only the OCTOPUS TPS enables fine scaling of
the eye model dimensions according to CT or MRI data.
However, none of the ocular structures can be segmented
directly from the MRI. Their definitions are still based on the
model itself. EYEPLAN as well as EOPP TPS define the tar-
get by modeling the shape of the tumor by using appropriate
degrees of a polynomial function that would match the best
the complexity of the uveal melanoma. Marnitz et al.47 com-
pared clinical tumor volumes generated by both EYEPLAN
and OCTOPUS, which derived from T1w and T2w 1.5 T
MRI slices with a dedicated surface coil. They observed a
systematic reduction of the clinical tumor volumes in the
OCTOPUS TPS over their patient cohort by a mean factor of
2.3 (T2w-based) and 1.7 (T1w-based), meaning that a model-
based method always overestimated tumor volumes. For an
accurate 3D description of the tumor and organs-at-risk, it is
crucial that 3D isotropic sequences are performed, since mul-
ti-slice sequences suffer from through plane motion artefacts
as not all slices are acquired simultaneously. This through
plane motion results in significant deformation of the image
in the slice direction, preventing an accurately reconstructed
MR-eye.
Although earlier studies have already reported on the use
of MRI for the diagnosis and, to a lesser extent, for the treat-
ment planning of uveal melanomas purpose,40,48,49 the clini-
cal impact of these studies was somewhat limited due to the
relatively low resolution images compared to current state-of-
the-art of MRI protocols in ocular oncology.23,24,26,50 In this
study, the increased signal at 7 Tesla MRI was employed, but
the recent advances in clinical 3 Tesla MRI allow for scans
with a similar 3D resolution. In order to achieve the same
image quality with a 3 Tesla MRI as with a 7 Tesla MRI, our
recent efforts have focused on developing digital receive
chains. A single coil is usually used to receive the 3 Tesla
MRI signal, but the integration of multi-element receive coils
would allow a significant reduction of the scanning time.23
The proposed 3D MRI-based treatment planning is field-
strength independent, thus enabling for a swift transition to
clinical practice.
A (0.3 mm)3 voxel size defining the 3D isotropic resolu-
tion of the reconstructed MRI images was used for the semi
auto-segmentation of optical structures and tumor volume.
This resolution is about twice as high as the inter observer
variability occurring with ultrasound measurements,51 which
is still the gold standard to determine base and maximum
tumor prominence. Nowadays, 3D MR-images with such a
resolution are sufficient to precisely and consistently assess a
wide spectrum of tumor dimensions, even regarding very
small tumors.24 Another relevant clinical concern relates to
an unclear presence of a flat extension.52 Although with
MRI, very small uveal melanoma can be visualized,24 flat
extensions of the tumor, which are less than a millimeter
thick, can easily be missed. The reconstructed patient MR-
eye should therefore always be validated with the fundus pho-
tography and any other available biometry measurements,
which were acquired for the diagnosis and therapy selection.
Even in the fully automated MRI-based treatment planning
workflow, the use of a multimodal imaging for diagnosis and
patients follow-up purposes remains indubitably important.52
The recent advances in anatomical and functional ophthalmic
MRI have spotted key parameters24 when imaging uveal mel-
anomas with good quality images, resulting in substantial
help in tumor contouring-making process. For some patients
(e.g., Fig. 1, patient 8) though, subretinal hemorrhage occur-
ring near the uveal melanoma may raise discussions while
evaluating the tumor edge. In these specific cases, the final
decision should therefore be achieved within a multi-disci-
plinary consensus.
Regarding the delineation of the organs-at-risk, the main
limitation was to segment the macula which was not visible
on any of the tested MRI sequences and therefore, only geo-
metrical assessment of its position and shape was imple-
mented. The difference in the optic nerve segmentation
between EOPP TPS and the MRI-based approach has multi-
ple reasons. The optic nerve in EOPP TPS is of tube-like
shape, and invariant during eye rotation. The tube has a lim-
ited length and the optic disc diameter has a fixed value that
cannot be modified by the user. It is the main important limi-
tation as the optic nerve shape is highly patient-dependent.
The ciliary body delineation is different to the geometrical
approach as only ciliary muscle is differentiable on the devel-
oped MRI sequences. Improvement of ciliary body delin-
eation as well as assessment on MR of macula and lacrimal
gland delineation (preventing dry eye syndromes53) is subject
of further studies.
None of the currently available treatment planning systems
directly incorporates 3D data for calculating the dose distri-
bution within the ocular structures. Dose calculation in the
EYEPLAN and EOPP TPS works with a surface sampling
(nodes) for isodoses generation. In the OCTOPUS TPS, the
real-time dose calculation is performed on the surface of the
eye model by modeling isodose surfaces as cylindrical layers
from the tessellated uveal melanoma boundaries including
safety margins.54 This is not directly performed in 3D voxels,
leading to a loss of information for very small ocular struc-
tures, which cannot be recovered.20,55 Dose calculation
engine pDose was developed in this study enabling the dose
calculation in 3D. However, it should be stressed that the
dose calculation remains crude, accounting in a tabulated
fashion for generic beam modifying devices. Therefore, fur-
ther work still has to be performed during the commissioning
phase to tune the algorithm specifically to a specific beamline
such as the one available at HollandPTC (Delft, The Nether-
lands), and to include the physics and dosimetric characteris-
tics of each beam modifying device.
In daily clinical practice, the choice of the optimal gazing
angle has to allow acceptable sparing of the most relevant
ocular organs-at-risk. In both available TPS, EYEPLAN and
EOPP, the selection of the optimal gazing angle is performed
by manual rotation of the eye model and evaluation of the
dose distribution. A complementary approach was recently
introduced by Hennings et al.19 with the concept of gazing
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angle-dependent mapping, where the number of organs-at-
risk with violated dose-volume constraints was displayed. In
their work, a tool for semi-automatic dose evaluation of all
clinically achievable gazing angles was built and the validity
of this concept was tested in a cohort of 48 patients. Con-
versely, in the approach presented in this manuscript, the pro-
ton dose distribution was calculated for every achievable
gazing angle and displayed as a grid map of values for the
global weighted-sum objective function. A trade-off for
organs-at-risk was manually and interactively obtained during
a forward optimization over the gazing angles of the solutions
space and tailored to the patient at hand, depending on
wished-objectives outcomes. This trade-off included a pen-
alty function for extreme gazing angles, which was so far per
se simple. Additional features will be added into pDose.
Firstly, dose optimization using a physical wedge will be
investigated, especially to reduce the dose to critical ocular
organs or to modify the needed modulation. Secondly, con-
straints and penalties for the head tilt and the chair position
will be included into a sophisticated function as, for example,
the tilting the head back makes it easier for a patient to look
up, but more difficult to look down. In this work, the calcula-
tion of the global weighted-sum objective functions still
remains a manual and time-consuming process but it is a first
step towards a more complex optimization in ocular proton
therapy, including above-mentioned features. A user-friendly
interface was developed to guide this planning step. There-
fore, by bringing everything together, another step might be
an automated multi-criteria optimization integrated into the
pipeline of pDose.56 This step will influence the complexity
of the algorithm but will not affect the speed of the calcula-
tion over the whole solutions space by automatically selecting
the optimal gazing angle(s) configuration.
During the treatment planning, commonly 2.5-mm mar-
gins are used. These margins encompass the following57: (a)
uncertainties in the physics setup beam line (including stop-
ping power ratio, range, penumbra); (b) uncertainties in the
axial eye-length and tumor height measurements via A- and
B-scans ultrasonography and ocular biometry; (c) uncertain-
ties in the geometrical eye model including clip positioning
error; (d) uncertainties in patient eye positioning and rotation;
and (e) inaccuracy in the in-room alignment with X-ray
images. The first and last aspects might only be improved by
technical developments coming up the next decades, which
in turn could increase accuracy of commissioning. However,
considering the dosimetric properties of the eyelines world-
wide using a passive scattering system, it is unlikely that sub-
stantial improvement will emerge from this area. With
regards to points (b) and (c), a dedicated 3D MRI-based treat-
ment planning approach will help to mitigate uncertainties at
the level of treatment planning, as the uveal melanoma, eye
globe and ocular structures can be more accurately seg-
mented. With regard to the patient eye positioning and rota-
tion, eye ball translation and involuntary eye movements
motion models, which are so far neglected in ocular proton
therapy planning, could be introduced and eventually, it could
mitigate these uncertainties. As in conventional radiotherapy,
limitation of these uncertainties, together with consideration
of random and systematic errors during the whole treatment
process, might lead to a better definition of margins in ocular
proton therapy. In fact, elaborating such a theoretical margin
recipe instead of using the consensus of 2.5-mm margin can
lead to a better organs-at-risk sparing. This recipe can result
in reduced complication probability while keeping the same
local tumor control for some clinical situations.
An ultimate aim of using MRI in ocular proton therapy is
a clipless treatment and to increase patient comfort. To
achieve this, not only an MRI-based TPS is needed but also a
real time eye detection system for gazing angle position veri-
fication before and during the treatment.58 At both Centro
Nazionale di Adroterapia Oncologica (CNAO, Pavia, Italy)
and Paul Scherrer Institute, eye tracking systems have been
embedded for controlling the gaze direction during the treat-
ment fraction.59–62 An infrared optical tracking-based camera
system is also under development within a broader collabora-
tion of this project for Image Guidance Proton Therapy
(IGPT). The clinical implementation of any of the investi-
gated systems will lead to avoiding the use of surgical clips
(tantalum, 2.5-mm diameter, 0.17-mm thickness), which
cause dose uncertainties behind and/or nearby due to the high
density of tantalum if located in the beam path. The density
of the tantalum material is not taken into account in both
EYEPLAN and EOPP TPS where only an average of eye den-
sity of 1.05 g.cm3 is assumed, although this value may be
adjusted and vary among the centers.13,63 The degree of dis-
turbance can be high as raised by Carnicer et al.64 who estab-
lished an underdose shadow of up to 20% downstream of
their location associated with an overdose on either side of
the beam paths and a shift reduction of 1.1 mm of the
intended range along the central axis of the beam. Newhauser
et al.65 reported dose perturbations between 22% and 82%,
when investigating various clip positions and orientations.
Likewise, the presence of acute hemorrhage or severe cataract
for some patients may disturb the clips placements, which, in
turn, may entail lower accuracy of tumor delineation.63 Egger
et al.5 highlighted the fact that inadequate positioning of tan-
talum clips has compromised tumor modeling and thus is
identified as a risk factor for local tumor control failure if the
target definition would be based purely on the X-ray imaging.
Although attempts have been studied for substituting tanta-
lum with other fiducial markers materials,66,67 tantalum still
remains the implanted metal of choice. Last but not least, the
stitching of the clips to the sclera is an invasive procedure sig-
nificantly reducing the patient comfort during the treatment.
Therefore, by avoiding clips in a well-established way, a 3D
MRI-based treatment planning approach using an automatic
gaze-angle optimization linked with a dedicated eye tracker
for daily treatment setup control could be the key to advance
ocular proton therapy.
5. CONCLUSION
In conclusion, accounting for real 3D ocular anatomy is
feasible using high-resolution MRI, and a dedicated
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treatment planning system has been successfully developed.
This new combined approach could lead to better selection of
the gazing angles depending on weights and organs-at-risk
constraints. This represents an important step towards a non-
invasive clinical protocol and improved treatment accuracy. It
opens additional investigation possibilities for ocular papilla
and macula MR segmentation, margins definition, multi-cri-
teria optimization, workflow validation, and clipless IGPT
procedure, which are the scope of ongoing and further
research.
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